GPHYSD3: A Potential Drug Target and Biomarker for Psychiatric Disorders

Target Name: LTBP3

NCBI ID: G4054

LTBP3

GPHYSD3: A Potential Drug Target and Biomarker for Psychiatric Disorders

LTBP3 (GPHYSD3) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative disorders, and psychiatric conditions. The gene is located on chromosome 12 and encodes for a protein known as GPHYSD3, which is involved in a variety of cellular processes, including cell signaling, DNA replication, and stress response.

Recent studies have suggested that GPHYSD3 may be a promising drug target for the treatment of cancer, neurodegenerative disorders, and psychiatric conditions. For example, GPHYSD3 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, GPHYSD3 has been linked to the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target, GPHYSD3 has also been identified as a potential biomarker for the diagnosis and monitoring of various psychiatric conditions, including depression, anxiety, and schizophrenia. This is because the expression of GPHYSD3 has been shown to be altered in individuals with psychiatric conditions, and may be a useful diagnostic tool for these conditions.

One potential mechanism by which GPHYSD3 may be involved in the development and progression of cancer is through its role in cell signaling. GPHYSD3 has been shown to be involved in a variety of signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cell growth and survival. Additionally, GPHYSD3 has been shown to be involved in the regulation of cell adhesion, which is important for the maintenance of tissue structure and the development of various diseases.

In addition to its potential role in cancer and neurodegenerative disorders, GPHYSD3 has also been suggested as a potential biomarker for psychiatric conditions. GPHYSD3 has been shown to be expressed in the brains of individuals with depression, anxiety, and schizophrenia, and may be a useful diagnostic tool for these conditions. Additionally, GPHYSD3 has been shown to be involved in the regulation of neurotransmitter synthesis and release, which is important for the function of the brain and may be involved in the development of psychiatric conditions.

Overall, GPHYSD3 is a gene that has the potential to be a drug target or biomarker for a variety of psychiatric and medical conditions. Further research is needed to fully understand the role of GPHYSD3 in these conditions and to develop effective treatments.

Protein Name: Latent Transforming Growth Factor Beta Binding Protein 3

Functions: Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space. Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta

The "LTBP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LTBP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets